Literature DB >> 15284308

Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?

Geert J Behets1, Geert Dams, Sven R Vercauteren, Stephen J Damment, Roger Bouillon, Marc E De Broe, Patrick C D'Haese.   

Abstract

Adequate control of phosphate levels remains an important issue in patients with chronic renal failure (CRF). Lanthanum carbonate has been proposed as a new phosphate binder. Previous studies have shown a high phosphate binding capacity (>97%) and low gastrointestinal absorption of lanthanum, without serious toxic side effects in the presence of a normal renal function (NRF). Because of lanthanum's physicochemical resemblance to calcium, the possible effects of it on bone have to be considered. The aim of this study was to investigate the effects of lanthanum carbonate on bone histology in NRF and CRF rats after oral administration of the compound with doses of 100, 500, or 1000 mg/kg per d for 12 wk. Bone histomorphometry showed that CRF animals that received vehicle developed secondary hyperparathyroidism. Urinalysis of lanthanum-loaded CRF animals showed a dose-dependent decrease in urinary phosphorus excretion, which was clearly more pronounced in the CRF groups compared with NRF animals. Phosphatemia, however, remained normal. Lanthanum carbonate administration induced a dose-dependent decrease in bone formation rate and increase in osteoid area in CRF animals. Three of seven animals in the CRF-1000 group and one of eight animals in the NRF-100 group were classified as having a mineralization defect. The number of cuboidal osteoblasts, however, was not affected, indicating that bone changes were not due to a toxic effect of lanthanum on the osteoblast. Furthermore, lanthanum concentrations in the femur remained low and did not correlate with histomorphometric parameters. These findings suggest that the administration of high doses of phosphate binder (1000 mg/kg per d lanthanum carbonate), in combination with decreased 25-(OH) vitamin D(3) in the uremic state, resulted in phosphate depletion and followed by an increased mobilization of phosphorus out of bone and/or reduced incorporation into bone. There was no evidence that lanthanum had a direct toxic effect on osteoblasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284308     DOI: 10.1097/01.ASN.0000133022.32912.95

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  16 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

Review 2.  In situ imaging of metals in cells and tissues.

Authors:  Reagan McRae; Pritha Bagchi; S Sumalekshmy; Christoph J Fahrni
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

3.  Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Authors:  Darbie Maccubbin; Diane Tipping; Olga Kuznetsova; William A Hanlon; Andrew G Bostom
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

4.  Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover.

Authors:  Toshio Fumoto; Masako Ito; Kyoji Ikeda
Journal:  J Bone Miner Metab       Date:  2013-10-15       Impact factor: 2.626

Review 5.  The Role of Bone Biopsy in the Management of CKD-MBD.

Authors:  Ana Carina Ferreira; Martine Cohen-Solal; Patrick C D'Haese; Aníbal Ferreira
Journal:  Calcif Tissue Int       Date:  2021-03-26       Impact factor: 4.333

6.  Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Authors:  Alastair J Hutchison; M Edwina Barnett; Rolfdieter Krause; Jonathan T C Kwan; Ghodrat A Siami
Journal:  Nephron Clin Pract       Date:  2008-07-31

7.  Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.

Authors:  Renske Raaijmakers; Lambertus M W Houkes; Cornelis H Schröder; Johannes L Willems; Leo A H Monnens
Journal:  Perit Dial Int       Date:  2013-05-01       Impact factor: 1.756

8.  Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.

Authors:  Osamu Kinoshita; Haruo Yamauchi; Noboru Motomura; Minoru Ono
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-10-29

9.  Pharmacology of the phosphate binder, lanthanum carbonate.

Authors:  Stephen J P Damment
Journal:  Ren Fail       Date:  2011       Impact factor: 2.606

10.  Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.

Authors:  Stephen Damment; Roger Secker; Victor Shen; Victor Lorenzo; Mariano Rodriguez
Journal:  Nephrol Dial Transplant       Date:  2010-11-22       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.